

# Liese Barbier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8036281/publications.pdf>

Version: 2024-02-01

12  
papers

269  
citations

1307594

7  
h-index

1281871

11  
g-index

13  
all docs

13  
docs citations

13  
times ranked

235  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging. <i>Frontiers in Medicine</i> , 2022, 9, 820755.  | 2.6  | 16        |
| 2  | When Will American Patients Start Benefitting From Biosimilars?. <i>Mayo Clinic Proceedings</i> , 2022, 97, 1044-1047.  | 3.0  | 1         |
| 3  | Off-Patent Biologicals and Biosimilars Tendering in Europe – A Proposal towards More Sustainable Practices. <i>Pharmaceuticals</i> , 2021, 14, 499.   | 3.8  | 18        |
| 4  | Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 53.                           | 2.4  | 7         |
| 5  | Community pharmacists' preparedness for substituting biologics and dispensing biosimilars – Lessons learned from a multinational survey. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2021, 4, 100084. | 1.0  | 2         |
| 6  | Interchangeability of Biosimilars: Overcoming the Final Hurdles. <i>Drugs</i> , 2021, 81, 1897-1903.  | 10.9 | 11        |
| 7  | Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care. <i>Frontiers in Pharmacology</i> , 2021, 12, 789640.  | 3.5  | 6         |
| 8  | European Stakeholder Learnings Regarding Biosimilars: Part II – Improving Biosimilar Use in Clinical Practice. <i>BioDrugs</i> , 2020, 34, 797-808.   | 4.6  | 33        |
| 9  | European Stakeholder Learnings Regarding Biosimilars: Part I – Improving Biosimilar Understanding and Adoption. <i>BioDrugs</i> , 2020, 34, 783-796.  | 4.6  | 39        |
| 10 | The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 734-755.                    | 4.7  | 86        |
| 11 | The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. <i>British Journal of Cancer</i> , 2019, 121, 199-210.   | 6.4  | 48        |
| 12 | Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking. <i>Frontiers in Pharmacology</i> , 0, 13, .   | 3.5  | 2         |